The numbers of T-cell receptors (TCRs) engaged, as well as the time of interaction with the major histocompatibility complex (MHC)–peptide complexes, determine whether T-cell activation occurs.
Bidirectional signaling along the B7–CTLA-4 coreceptor pathway enables reciprocal conditioning of T cells and dendritic cells. Although T cells can instruct dendritic cells to manifest tolerogenic ...
Adding CD28 costimulation to cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity ...
A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in metastatic hormone sensitive prostate cancer patients with HRR gene mutation: Updated analysis ...
Significant progress in understanding T cell signalling, particularly with respect to T cell co-receptors such as the co-stimulatory receptor CD28, has been made in recent years. This knowledge has ...
-- Research collaboration focused on the discovery of novel bispecific antibodies directed toward the CD28 co-stimulatory receptor and an undisclosed prostate tumor target -- -- Xencor receives $50 ...
HAYWARD, Calif.--(BUSINESS WIRE)--Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for ...
Alpine Immune Sciences turned heads a year ago when AbbVie formed a deal with the company worth up to $805 million in milestone payments for a first-in-class lupus drug that inhibits a protein on the ...
With analysts looking for a meaningful increase in the number of responses for Regeneron's phase 1/2 solid tumor trial, a fresh data slice shows just one complete response across 94 patients.
The collaboration will combine Rondo’s proprietary CD28 co-stimulatory platform with Lilly’s drug development and commercialization expertise to develop co-stimulatory bispecific antibodies to treat ...
Hypervigilance: A phase Ib clinical trial to optimize risk-benefit of nezastomig (PSMAxCD28 costimulatory bispecific antibody) plus cemiplimab (anti-PD-1) in patients with metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results